BizDataDive: Why does a new drug require joint R&D?
retained text
Choose your language
By continuing to browse our site you agree to our use of cookies, revised Privacy Policy and Terms of Use. You can change your cookie settings through your browser.
I agree
Economy
21:00, 20-Sep-2026
01:56
China has a third of the world's innovative drugs-in-development, while the US contributes 55% of global biopharma R&D investment. When these strengths meet, multi-billion-dollar partnerships follow—and patients worldwide benefit.
In this episode, we explore why drug development knows no borders.
Search Trends
DOWNLOAD OUR APP
Copyright © 2026 CGTN.
京ICP备20000184号
京公网安备 11010502050052号
互联网新闻信息许可证10120180008
Disinformation report hotline: 010-85061466document fetched 2026-09-22 02:52 · canonical https://news.cgtn.com/news/2026-09-20/BizDataDive-Why-does-a-new-drug-require-joint-R-D--1Qzb2NQAKv6/p.html